

<b>Table E1</b> Eosinophils (cells/ $\mu$ L) pre- and post-HSCT for DOCK8 deficiency		
Patient	Pre-HSCT	Post-HSCT (months post-HSCT)
1	840	10 (36.2)
3	2080	140 (28.4)
4	2100	720 (33.5)
6	19540	450 (27.2)
8	21940	440 (36.0)
9	2790	80 (37.7)
10	2700	170 (22.2)
11	430	140 (29.7)

<b>Table E2</b> Lymphocyte subsets pre- and post-HSCT for DOCK8 deficiency				
Subset	Patient	Pre-HSCT	Post-HSCT (months post-HSCT)	
CD3+ (cells/ $\mu$ L)	1	<b>485</b>	1566 (36.2)	
	3	<b>685</b>	2253 (28.4)	
	4	<b>764</b>	1862 (33.5)	
	5	<b>784</b>	1819 (13.4)	
	6	<b>980</b>	2165 (27.2)	
	8	2760	1570 (23.4)	
	9	1350	2459 (37.7)	
	10	2550	3110 (22.0)	
	11	<b>2015</b>	2182 (29.7)	
	CD4+ (cells/ $\mu$ L)	1	<b>295</b>	870 (36.2)
		3	<b>205</b>	1065 (28.4)
4		<b>247</b>	<b>489 (33.5)</b>	
5		<b>591</b>	1300 (13.4)	
6		<b>433</b>	923 (27.2)	
8		1010	890 (23.4)	
9		1045	1310 (37.7)	
10		2240	1510 (22.0)	
11		<b>889</b>	988 (29.7)	
CD8+ (cells/ $\mu$ L)		1	<b>186</b>	648 (36.2)
		3	<b>405</b>	1072 (28.4)
	4	397	1025 (33.5)	
	5	<b>159</b>	451 (13.4)	
	6	449	1022 (27.2)	
	8	1650	570 (23.4)	
	9	<b>295</b>	1049 (37.7)	
	10	<b>310</b>	1360 (22.0)	
	11	1061	1098 (29.7)	
	CD4/CD8	1	1.59	1.34 (36.2)
		3	<b>0.51</b>	<b>0.99 (28.4)</b>
4		<b>0.62</b>	<b>0.48 (33.5)</b>	
5		3.72	2.88 (13.4)	
6		<b>0.96</b>	0.89 (27.2)	
8		<b>0.61</b>	1.56 (23.4)	
9		3.54	1.25 (37.7)	
10		7.23	1.11 (22.0)	
11		<b>0.84</b>	0.90 (29.7)	
CD19+ (cells/ $\mu$ L)		1	1426	385 (36.2)
		3	272	1209 (28.4)
	4	<b>127</b>	640 (33.5)	
	5	<b>495</b>	758 (13.4)	
	6	<b>208</b>	944 (27.2)	
	8	1750	660 (23.4)	
	9	518	686 (37.7)	
	10	2040	1166 (22.2)	
	11	2306	<b>317 (29.7)</b>	

CD56/16+ (cells/ $\mu$ L)	1	161	135 (36.2)
	3	<b>37</b>	132 (28.4)
	4	130	350 (33.5)
	5	<b>126</b>	<b>79 (13.4)</b>
	6	349	168 (27.2)
	8	580	170 (23.4)
	9	214	187 (37.7)
	10	<b>100</b>	535 (22.2)
	11	<b>151</b>	<b>80 (29.7)</b>
CD4+CD45RA+ (%)	1	<b>48.8</b>	56.5 (36.2)
	4	<b>0.2</b>	45.5 (33.5)
	5	73.1	55 (13.4)
	6	56.3	<b>44.4 (27.2)</b>
	8	59	51.3 (23.4)
	10	78.2	<b>36 (22.0)</b>
	11	<b>56.3</b>	56.1 (29.7)
CD8+CD45RA+ (%)	1	<b>6.1</b>	78.4 (36.2)
	4	<b>0.9</b>	76.1 (33.5)
	6	<b>6.8</b>	80.2 (27.2)
	8	86	<b>50 (23.4)</b>
	10	85.8	<b>47 (22.0)</b>
	11	<b>3.5</b>	<b>47.1 (29.7)</b>
CD19+CD27+IgD- (%)	1	<b>0.6</b>	<b>3 (36.2)</b>
	3	<b>0.8</b>	<b>2.5 (28.4)</b>
	6	<b>2.4</b>	<b>9.2 (27.2)</b>
	11	<b>0.6</b>	13.7 (29.7)
CD19+CD27+IgD+ (%)	1	<b>2.1</b>	<b>4.2 (36.2)</b>
	3	<b>1</b>	<b>3.6 (28.4)</b>
	6	<b>3.4</b>	7 (27.2)
	11	<b>2.4</b>	13.8 (29.7)
Bold values are abnormally low for age			

**FIG E1.** DOCK8 expression by flow cytometry in peripheral blood cells. A, Control and patient P4, pre-HSCT. B, Control and P7 (post-rituximab) pre-HSCT. *Shaded histograms* indicate isotype control.

